Pfizer Share Holder Equity 2010-2024 | PFE
Pfizer share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
- Pfizer share holder equity for the quarter ending September 30, 2024 was $87.975B, a 11.4% decline year-over-year.
- Pfizer share holder equity for 2023 was $89.288B, a 6.91% decline from 2022.
- Pfizer share holder equity for 2022 was $95.916B, a 23.82% increase from 2021.
- Pfizer share holder equity for 2021 was $77.462B, a 22.04% increase from 2020.
Pfizer Annual Share Holder Equity
(Millions of US $) |
| 2023 |
$89,288 |
| 2022 |
$95,916 |
| 2021 |
$77,462 |
| 2020 |
$63,473 |
| 2019 |
$63,447 |
| 2018 |
$63,758 |
| 2017 |
$71,656 |
| 2016 |
$59,840 |
| 2015 |
$64,998 |
| 2014 |
$71,622 |
| 2013 |
$76,620 |
| 2012 |
$81,678 |
| 2011 |
$82,621 |
| 2010 |
$88,265 |
| 2009 |
$90,446 |
Pfizer Quarterly Share Holder Equity
(Millions of US $) |
| 2024-06-30 |
$87,975 |
| 2024-03-31 |
$92,558 |
| 2023-12-31 |
$89,288 |
| 2023-09-30 |
$97,204 |
| 2023-06-30 |
$99,293 |
| 2023-03-31 |
$101,236 |
| 2022-12-31 |
$95,916 |
| 2022-09-30 |
$92,891 |
| 2022-06-30 |
$87,469 |
| 2022-03-31 |
$82,685 |
| 2021-12-31 |
$77,462 |
| 2021-09-30 |
$75,967 |
| 2021-06-30 |
$70,315 |
| 2021-03-31 |
$68,865 |
| 2020-12-31 |
$63,473 |
| 2020-09-30 |
$65,495 |
| 2020-06-30 |
$64,564 |
| 2020-03-31 |
$65,338 |
| 2019-12-31 |
$63,447 |
| 2019-09-30 |
$65,396 |
| 2019-06-30 |
$59,924 |
| 2019-03-31 |
$59,158 |
| 2018-12-31 |
$63,758 |
| 2018-09-30 |
$71,664 |
| 2018-06-30 |
$70,124 |
| 2018-03-31 |
$70,541 |
| 2017-12-31 |
$71,656 |
| 2017-09-30 |
$61,110 |
| 2017-06-30 |
$58,694 |
| 2017-03-31 |
$58,746 |
| 2016-12-31 |
$59,840 |
| 2016-09-30 |
$63,601 |
| 2016-06-30 |
$63,066 |
| 2016-03-31 |
$63,347 |
| 2015-12-31 |
$64,998 |
| 2015-09-30 |
$67,124 |
| 2015-06-30 |
$67,180 |
| 2015-03-31 |
$67,587 |
| 2014-12-31 |
$71,622 |
| 2014-09-30 |
$78,305 |
| 2014-06-30 |
$76,956 |
| 2014-03-31 |
$78,068 |
| 2013-12-31 |
$76,620 |
| 2013-09-30 |
$78,354 |
| 2013-06-30 |
$78,977 |
| 2013-03-31 |
$82,827 |
| 2012-12-31 |
$81,678 |
| 2012-09-30 |
$82,115 |
| 2012-06-30 |
$79,961 |
| 2012-03-31 |
$83,677 |
| 2011-12-31 |
$82,621 |
| 2011-09-30 |
$90,530 |
| 2011-06-30 |
$88,963 |
| 2011-03-31 |
$90,533 |
| 2010-12-31 |
$88,265 |
| 2010-09-30 |
$88,068 |
| 2010-06-30 |
$86,878 |
| 2010-03-31 |
$90,082 |
| 2009-12-31 |
$90,446 |
| 2009-09-30 |
$66,250 |
| 2009-06-30 |
$63,235 |
| 2009-03-31 |
$60,441 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$159.177B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
